XT
ARTV

XTX Topco’s Artiva Biotherapeutics ARTV Stock Holding History

XTX Topco’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$412K Buy
42,509
+22,239
+110% +$203K 0.01% 2633
2026
Q1 		$131K Buy
+20,270
New +$100K ﹤0.01% 3013
2025
Q4 		– Sell
-47,973
Closed -$138K – 3915
2025
Q3 		$138K Buy
+47,973
New +$128K 0.01% 1952

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

XTX Topco's ARTV Position: Q2 2026 in Review

XTX Topco increased its Artiva Biotherapeutics (ARTV) stake by 110% in Q2 2026, buying an estimated $203K and bringing the position to 42,509 shares worth $412K. The position accounts for 0.01% of the portfolio, ranked #2633.

XTX Topco first reported a position in ARTV in Q3 2025 and has held it in 3 quarters since. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • XTX Topco held 42,509 shares of Artiva Biotherapeutics worth $412K as of Q2 2026.
  • XTX Topco bought 22,239 Artiva Biotherapeutics shares in Q2 2026, an estimated $203K.
  • Artiva Biotherapeutics made up 0.01% of XTX Topco's portfolio in Q2 2026, its #2633 holding.
  • XTX Topco first reported a position in Artiva Biotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.